EU approves Fycompa (Eisai) for treatment of Epilepsy - 29-Jul-2012

The European Commission has granted marketing authorisation approval for the use of Fycompa (perampanel) from Eisai as an adjunctive treatment of partial-onset seizures, with or without secondarily generalised seizures, in people with Epilepsy aged 12 years and older.The FDA issued a refusal to file letter for perampanel in July 2011, following a preliminary review of the acceptability of the original data package submitted the previous May. A resubmission from Eisai was accepted for review by the FDA in March this year.

Related News

Related Neurological Disorders Information

Related Neurological Disorders Drugs

Back to top

Latest News

10 May 2015
18 May 2013
18 May 2013